Appetite for Change: The Obesity Epidemic Meets Biotech
Obesity is a global health crisis. With over 650 million adults affected worldwide, it drives massive economic and disease burdens. Yet new treatment options like an oral GLP-1 drug can offer hope.
Episode four of Unseen Upside: Investments Beyond Their Returns analyzes the investment landscape and future of obesity therapeutics, focusing on transformational GLP-1 drugs like Ozempic that curb appetite. Join us as we investigate the promise and challenges of emerging anti-obesity drugs, learn about one patient’s journey taking them, and discover what the future of weight loss medicine could look like.
We’ll hear from leaders in this space as well as one patient. Guests include:
- Rod Wong, Founder, Managing Partner, and Chief Investment Officer at RTW Investments
- Raymond Stevens, Ph.D., Chief Executive Officer at Structure Therapeutics
- Dean Dimizas, Partner and Managing Director at Cambridge Associates
- Kathleen Mikaelian, Patient
Listen below or wherever you get your podcasts.
Explore more episodes
Listen nowAbout
Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.
Enjoying the podcast? Subscribe, rate, and review Unseen Upside: Investments Beyond Their Returns on Apple Podcasts and Spotify.
Have an idea for an episode or interested in being a guest? Email unseenupside@cambridgeassociates.com to get involved.